Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation

Dorota Frydecka, Błażej Misiak, Edyta Pawlak-Adamska, Lidia Karabon, Anna Tomkiewicz, Paweł Sedlaczek, Andrzej Kiejna, Jan Aleksander Beszłej, Dorota Frydecka, Błażej Misiak, Edyta Pawlak-Adamska, Lidia Karabon, Anna Tomkiewicz, Paweł Sedlaczek, Andrzej Kiejna, Jan Aleksander Beszłej

Abstract

The influence of the immune system deregulation on the risk of schizophrenia is increasingly recognized. The aim of this study was to assess the influence of serum interleukin-6 (IL-6) level together with the polymorphism in its gene (IL6 -174G/C) and high sensitivity C-reactive protein (hsCRP) levels on clinical manifestation and cognition in schizophrenia patients. We recruited 151 patients with schizophrenia and 194 healthy control subjects. Psychopathology was evaluated using Operational Criteria for Psychotic Illness checklist, Positive and Negative Syndrome Scale (PANSS) and Scales for Assessment of Positive and Negative Symptoms. Cognitive performance in schizophrenia patients was assessed using following tests: Rey Auditory Verbal Learning Test, Trail Making Test, Verbal Fluency Tests, Stroop and subscales from Wechsler Adults Intelligence Scale-R-Pl (Similarities, Digit Symbol Coding, Digit Span Forward and Backward). Serum IL-6 and hsCRP levels were significantly higher in schizophrenia patients in comparison with healthy controls. Both hsCRP and IL-6 levels were associated with insidious psychosis onset, duration of illness and chronic schizophrenia course with deterioration. After adjustment for age, education level, number of years of completed education, illness duration, total PANSS score, depression severity and chlorpromazine equivalent, there was still a positive association between IL-6 and hsCRP levels and worse cognitive performance. The IL6 -174G/C polymorphism did not influence IL-6 level, but it was associated with the severity of positive symptoms. Our results suggest that elevated IL-6 levels may play the role in cognitive impairment and serve as potential inflammatory biomarker of deterioration in schizophrenia.

Figures

Fig. 1
Fig. 1
The comparison of hsCRP and IL-6 (p > 0.05 and p = 0.01, respectively) levels among patients with different course of schizophrenia (multiple episodes with good or partial recovery between episodes, continuous chronic illness, continuous chronic illness with deterioration)

References

    1. Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Interleukin-6: structure-function relationships. Protein Sci. 1997;6(5):929–955. doi: 10.1002/pro.5560060501.
    1. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63(8):801–808. doi: 10.1016/j.biopsych.2007.09.024.
    1. Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, Greenberg AH. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994;643(1–2):40–49. doi: 10.1016/0006-8993(94)90006-X.
    1. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–671. doi: 10.1016/j.biopsych.2011.04.013.
    1. Stojanovic A, Martorell L, Montalvo I, Ortega L, Monseny R, Vilella E, Labad J. Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms. Psychoneuroendocrinology. 2014;41:23–32. doi: 10.1016/j.psyneuen.2013.12.005.
    1. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, Pioli R, Altamura C, Scharpe S, Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res. 1998;32(1):9–15. doi: 10.1016/S0920-9964(98)00034-6.
    1. Ganguli R, Yang Z, Shurin G, Chengappa KN, Brar JS, Gubbi AV, Rabin BS. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res. 1994;51(1):1–10. doi: 10.1016/0165-1781(94)90042-6.
    1. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem. 2000;275(24):18138–18144. doi: 10.1074/jbc.M000379200.
    1. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Investig. 1998;102(7):1369–1376. doi: 10.1172/JCI2629.
    1. Zakharyan R, Petrek M, Arakelyan A, Mrazek F, Atshemyan S, Boyajyan A. Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. Tissue Antigens. 2012;80(2):136–142. doi: 10.1111/j.1399-0039.2012.01886.x.
    1. Paul-Samojedny M, Kowalczyk M, Suchanek R, Owczarek A, Fila-Danilow A, Szczygiel A, Kowalski J. Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia: a case–control study. Journal of molecular neuroscience : MN. 2010;42(1):112–119. doi: 10.1007/s12031-010-9365-6.
    1. Frydecka D, Misiak B, Beszlej JA, Karabon L, Pawlak-Adamska E, Tomkiewicz A, Partyka A, Jonkisz A, Kiejna A. Genetic variants in transforming growth factor-beta gene (TGFB1) affect susceptibility to schizophrenia. Mol Biol Rep. 2013
    1. Paul-Samojedny M, Owczarek A, Kowalczyk M, Suchanek R, Palacz M, Kucia K, Fila-Danilow A, Borkowska P, Kowalski J. Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFalpha) gene polymorphisms with paranoid schizophrenia in a Polish population. J Neuropsychiatry Clin Neurosci. 2013;25(1):72–82. doi: 10.1176/appi.neuropsych.12020021.
    1. Debnath M, Mitra B, Bera NK, Chaudhuri TK, Zhang YP. Lack of association of IL-6 (-174 G > C) and TNF-alpha (-238 G > A) variants with paranoid schizophrenia in Indian Bengalee population. Cytokine. 2013;61(2):455–458. doi: 10.1016/j.cyto.2012.10.028.
    1. Liu YL, Liu CM, Fann CS, Yang WC, Chen YH, Tseng LJ, Liu SK, Hsieh MH, Hwang TJ, Chan HY, Chen JJ, Chen WJ, Hwu HG. Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan. Neurosci Lett. 2010;468(3):330–333. doi: 10.1016/j.neulet.2009.11.026.
    1. Gimeno D, Marmot MG, Singh-Manoux A. Inflammatory markers and cognitive function in middle-aged adults: the Whitehall II study. Psychoneuroendocrinology. 2008;33(10):1322–1334. doi: 10.1016/j.psyneuen.2008.07.006.
    1. Marsland AL, Petersen KL, Sathanoori R, Muldoon MF, Neumann SA, Ryan C, Flory JD, Manuck SB. Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom Med. 2006;68(6):895–903. doi: 10.1097/01.psy.0000238451.22174.92.
    1. Simpson EE, Hodkinson CF, Maylor EA, McCormack JM, Rae G, Strain S, Alexander HD, Wallace JM. Intracellular cytokine production and cognition in healthy older adults. Psychoneuroendocrinology. 2013;38(10):2196–2208. doi: 10.1016/j.psyneuen.2013.04.007.
    1. Mooijaart SP, Sattar N, Trompet S, Lucke J, Stott DJ, Ford I, Jukema JW, Westendorp RG, de Craen AJ. Circulating interleukin-6 concentration and cognitive decline in old age: the PROSPER study. J Intern Med. 2013;274(1):77–85. doi: 10.1111/joim.12052.
    1. Heringa SM, van den Berg E, Reijmer YD, Nijpels G, Stehouwer CD, Schalkwijk CG, Teerlink T, Scheffer PG, van den Hurk K, Kappelle LJ, Dekker JM, Biessels GJ. Markers of low-grade inflammation and endothelial dysfunction are related to reduced information processing speed and executive functioning in an older population - the Hoorn Study. Psychoneuroendocrinology. 2014;40:108–118. doi: 10.1016/j.psyneuen.2013.11.011.
    1. Jordanova V, Stewart R, Davies E, Sherwood R, Prince M. Markers of inflammation and cognitive decline in an African-Caribbean population. Int J Geriatr Psychiatry. 2007;22(10):966–973. doi: 10.1002/gps.1772.
    1. Lekander M, von Essen J, Schultzberg M, Andreasson AN, Garlind A, Hansson LO, Nilsson LG. Cytokines and memory across the mature life span of women. Scand J Psychol. 2011;52(3):229–235. doi: 10.1111/j.1467-9450.2010.00865.x.
    1. Grassi-Oliveira R, Bauer ME, Pezzi JC, Teixeira AL, Brietzke E. Interleukin-6 and verbal memory in recurrent major depressive disorder. Neuro Endocrinol Lett. 2011;32(4):540–544.
    1. Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol. 2012;213:11–37. doi: 10.1007/978-3-642-25758-2_2.
    1. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93(1–3):261–265. doi: 10.1016/j.schres.2007.03.022.
    1. Muller N, Myint AM, Schwarz MJ. Immunological treatment options for schizophrenia. Curr Pharm Biotechnol. 2012;13(8):1606–1613. doi: 10.2174/138920112800784826.
    1. Nitta M, Kishimoto T, Muller N, Weiser M, Davidson M, Kane JM, Correll CU. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013;39(6):1230–1241. doi: 10.1093/schbul/sbt070.
    1. Sommer IE, de Witte L, Begemann M, Kahn RS. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73(4):414–419. doi: 10.4088/JCP.10r06823.
    1. Muller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2005;255(2):149–151. doi: 10.1007/s00406-004-0548-4.
    1. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry. 1991;48(8):764–770. doi: 10.1001/archpsyc.1991.01810320088015.
    1. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64(6):663–667. doi: 10.4088/JCP.v64n0607.
    1. Rey A. The clinical examination in psychology. Paris: University Press of France; 1964.
    1. Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol. 1955;19(5):393–394. doi: 10.1037/h0044509.
    1. Benton AL. Differential behavioural effects in frontal lobe disease. Neuropsychologia. 1968;6:53–60. doi: 10.1016/0028-3932(68)90038-9.
    1. Kessler J, Denzler P, Markowitsch HJ (1988) Manual Demenz Test - Wrotproduktion (“Supermarktaufgabe). Dementznormen. 10
    1. Jensen AR. Scoring the stroop test. Acta Psychol. 1965;24(5):398–408. doi: 10.1016/0001-6918(65)90024-7.
    1. Liu YL, Liu CM, Fann CS, Yang WC, Chen YH, Tseng LJ, Liu SK, Hsieh MH, Hwang TJ, Chan HY, Chen JJ, Chen WJ, Hwu HG. Genetic variants of IL-6 and its receptor are not associated with schizophrenia in Taiwan. Neurosci Lett. 2010;468(3):330–333. doi: 10.1016/j.neulet.2009.11.026.
    1. Dimitrov DH, Lee S, Yantis J, Valdez C, Paredes RM, Braida N, Velligan D, Walss-Bass C. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res. 2013;151(1–3):29–35. doi: 10.1016/j.schres.2013.10.019.
    1. Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res. 2000;44(3):165–175. doi: 10.1016/S0920-9964(99)00171-1.
    1. Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A, Jones RN, Mukherjee S, Curtis SM, Harvey D, Weiner M, Mungas D. Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Brain Imaging Behav. 2012;6(4):502–516. doi: 10.1007/s11682-012-9186-z.
    1. Manglam MK, Das A. Verbal learning and memory and psychopathology in schizophrenia. Asian J Psychiatr. 2013;6(5):417–420. doi: 10.1016/j.ajp.2013.05.009.
    1. Ekerholm M, Firus Waltersson S, Fagerberg T, Soderman E, Terenius L, Agartz I, Jonsson EG, Nyman H. Neurocognitive function in long-term treated schizophrenia: a five-year follow-up study. Psychiatry Res. 2012;200(2–3):144–152. doi: 10.1016/j.psychres.2012.05.008.
    1. van den Kommer TN, Dik MG, Comijs HC, Jonker C, Deeg DJ. Homocysteine and inflammation: predictors of cognitive decline in older persons? Neurobiol Aging. 2010;31(10):1700–1709. doi: 10.1016/j.neurobiolaging.2008.09.009.
    1. Dickinson D, Ramsey ME, Gold JM. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry. 2007;64(5):532–542. doi: 10.1001/archpsyc.64.5.532.
    1. Dickinson D. Digit symbol coding and general cognitive ability in schizophrenia: worth another look? Br J Psychiatry. 2008;193(5):354–356. doi: 10.1192/bjp.bp.108.049387.
    1. Rafnsson SB, Deary IJ, Smith FB, Whiteman MC, Rumley A, Lowe GD, Fowkes FG. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J Am Geriatr Soc. 2007;55(5):700–707. doi: 10.1111/j.1532-5415.2007.01158.x.
    1. Marioni RE, Strachan MW, Reynolds RM, Lowe GD, Mitchell RJ, Fowkes FG, Frier BM, Lee AJ, Butcher I, Rumley A, Murray GD, Deary IJ, Price JF. Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes. 2010;59(3):710–713. doi: 10.2337/db09-1163.
    1. Miller BJ, Culpepper N, Rapaport MH (2013) C-reactive protein levels in schizophrenia: a review and meta-analysis. Clin Schizophr Relat Psychoses 7(4):223–230. doi:10.3371/CSRP.MICU.020813
    1. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yang S, Yolken R. C-reactive protein is elevated in schizophrenia. Schizophr Res. 2013;143(1):198–202. doi: 10.1016/j.schres.2012.10.041.
    1. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, Justicia A, Bernardo M, Kirkpatrick B. Inflammatory markers in antipsychotic-naive patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res. 2012;198(2):212–215. doi: 10.1016/j.psychres.2011.08.014.
    1. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yang S, Yolken R. C-reactive protein is elevated in schizophrenia. Schizophr Res. 2013;143(1):198–202. doi: 10.1016/j.schres.2012.10.041.
    1. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 2007;93(1–3):261–265. doi: 10.1016/j.schres.2007.03.022.
    1. Dickerson F, Stallings C, Origoni A, Vaughan C, Khushalani S, Yolken R. Elevated C-reactive protein and cognitive deficits in individuals with bipolar disorder. J Affect Disord. 2013;150(2):456–459. doi: 10.1016/j.jad.2013.04.039.
    1. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 2007;149(1–3):267–271. doi: 10.1016/j.psychres.2006.07.011.
    1. Dunjic-Kostic B, Jasovic-Gasic M, Ivkovic M, Radonjic NV, Pantovic M, Damjanovic A, Poznanovic ST, Jovanovic A, Nikolic T, Petronijevic ND. Serum levels of interleukin-6 and tumor necrosis factor-alpha in exacerbation and remission phase of schizophrenia. Psychiatria Danubina. 2013;25(1):55–61.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit